Advanced Accelerator Applications
(Contributor support)

Advanced Accelerator Applications, S.A. (AAA), a Novartis company, is an innovative medicines company developing targeted radioligand therapies and precision imaging radioligands for oncology indications. We are committed to transforming patients’ lives by leading innovation in nuclear medicine.

Founded in 2002, AAA has a legacy as a pioneer in the development and delivery of radiopharmaceutical drugs for diagnostic imaging. More recently, AAA has focused its efforts on developing targeted radioligand therapies and precision imaging diagnostics that target specific markers that are over-expressed by certain types of solid tumors. AAA currently employs more than 1,100 associates across 31 sites in 12 countries; with 19 manufacturing facilities in 8 countries and 6 research and development sites.

Clinical Trials

An overview of the AAA pipeline for targeted radioligand therapy and precision imaging.


Disease Education

Pocket PSMA: Explore the Science of Targeted Radioligands. 


PSMA in Prostate Cancer

Learn about the role of PSMA in precision medicine for prostate cancer.

PSMA Expression and Relevance in Advanced Prostate Cancer

Prostate-specific membrane antigen (PSMA), a biomarker highly expressed on prostate cancer cells, is a potential target under investigation for diagnostic imaging and potential therapy.

[68Ga]Ga-PSMA-11 and [177Lu]Lu-PSMA-617 Mechanism of Action

Explore the mechanism of action of targeted radioligand therapy (RLT) –
[68Ga]Ga-PSMA-11 and [177Lu]Lu-PSMA-617.